Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04870073
Other study ID # RAPPER-MAN_2021
Secondary ID
Status Withdrawn
Phase Phase 3
First received
Last updated
Start date September 21, 2022
Est. completion date September 21, 2022

Study information

Verified date February 2023
Source Hamilton Health Sciences Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hemodilution reduces concentrations of blood constituents: concentration of hemoglobin, red blood cells (hematocrit), physiological ions and coagulation factors that can contribute to impaired hemostasis and increasing the risk of perioperative blood transfusions. This pilot study will assess the feasibility of a large RCT to evaluate 2 techniques for reducing hemodilution during cardiac surgery: 1) retrograde autologous priming and 2) intraoperative mannitol. The aim of this pilot trial is to demonstrate feasibility of a larger trial to evaluate whether retrograde autologous priming and/or mannitol are superior to conventional priming alone.


Description:

The use of large volumes of artificial priming fluids is still very high in cardiac surgery for routine CABG surgery with cardiopulmonary bypass. The resulting hemodilution is deleterious for patients and often requires counter measures to maintain fluid balance during and after surgery. Retrograde autologous priming and mannitol are simple low-cost solutions to the problem of hemodilution but their effectiveness, either alone or in combination, is unclear due to a lack of high-quality evidence. RAPPER-MAN is a single-centre 2x2 factorial cluster randomized trial. Participants will be randomly assigned (1:1:1:1 ratio) to the intervention groups: 1) Retrograde autologous priming (≥600 mL) + mannitol (0.3 g/kg bolus), 2) Retrograde autologous priming (≥600 mL) alone, 3) Conventional priming + mannitol (0.3 g/kg bolus), and 4) Conventional priming alone. The primary outcome is the change in hemoglobin concentration during cardiopulmonary bypass. Retrograde autologous priming will be performed within 10 minutes before, and mannitol will be added to the venous reservoir of the CPB machine within 5 minutes before, the start of cardiopulmonary bypass. The results of the larger trial are expected to have broad implications for fluid management in cardiac surgery in Canada.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date September 21, 2022
Est. primary completion date September 21, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. =18 years of age. 2. Undergoing a first-time cardiac surgical procedure (i.e. isolated CABG, isolated single cardiac valve surgery or a combination of both or isolated ascending aorta replacement) with the use of cardiopulmonary bypass (CPB) and median sternotomy. Exclusion Criteria: 1. Left ventricle ejection fraction <25% 2. Emergency surgery 3. History of bleeding disorder 4. Inherited thromboembolic or infective endocarditis (active) 5. Previous cardiac surgery 6. Severe renal impairment (serum creatinine >250 µmol/L) 7. Hemoglobin <80 g/L 8. Thrombocytopenia (<50,000 platelets per µL) 9. Expected circulatory arrest 10. Body weight =50 kg 11. Allergy to mannitol 12. Pregnancy or breast feeding

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Retrograde autologous priming
Priming solution (=600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team.
Drug:
Mannitol
Mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.
Procedure:
Conventional Priming
The conventional priming procedure will be used in the standardized cardiopulmonary machine used at the Hamilton General Hospital.

Locations

Country Name City State
Canada Hamilton General Hospital Hamilton Ontario

Sponsors (2)

Lead Sponsor Collaborator
Hamilton Health Sciences Corporation McMaster University

Country where clinical trial is conducted

Canada, 

References & Publications (4)

Hensley NB, Gyi R, Zorrilla-Vaca A, Choi CW, Lawton JS, Brown CH 4th, Frank SM, Grant MC, Cho BC. Retrograde Autologous Priming in Cardiac Surgery: Results From a Systematic Review and Meta-analysis. Anesth Analg. 2021 Jan;132(1):100-107. doi: 10.1213/ANE.0000000000005151. — View Citation

Ljunggren M, Skold A, Dardashti A, Hyllen S. The use of mannitol in cardiopulmonary bypass prime solution-Prospective randomized double-blind clinical trial. Acta Anaesthesiol Scand. 2019 Nov;63(10):1298-1305. doi: 10.1111/aas.13445. Epub 2019 Jul 29. — View Citation

Task Force on Patient Blood Management for Adult Cardiac Surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology (EACTA); Boer C, Meesters MI, Milojevic M, Benedetto U, Bolliger D, von Heymann C, Jeppsson A, Koster A, Osnabrugge RL, Ranucci M, Ravn HB, Vonk ABA, Wahba A, Pagano D. 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. J Cardiothorac Vasc Anesth. 2018 Feb;32(1):88-120. doi: 10.1053/j.jvca.2017.06.026. Epub 2017 Sep 30. No abstract available. — View Citation

Trapp C, Schiller W, Mellert F, Halbe M, Lorenzen H, Welz A, Probst C. Retrograde Autologous Priming as a Safe and Easy Method to Reduce Hemodilution and Transfusion Requirements during Cardiac Surgery. Thorac Cardiovasc Surg. 2015 Oct;63(7):628-34. doi: 10.1055/s-0035-1548731. Epub 2015 Mar 24. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Blood transfusion Proportion of patients experiencing red blood cell transfusion Start of surgery to hospital discharge or 5 days maximum (whichever occurs first)
Other Change in oxygen consumption during cardiopulmonary bypass Change in oxygen consumption during cardiopulmonary bypass Start to end of cardiopulmonary bypass
Other Autologous prime volume Total prime volume removed from the extracorporeal circuit during the retrograde autologous priming procedure Within 10 minutes before cardiopulmonary bypass
Other Hyponatremia Sodium concentration of less than 135 mmol/L (135 mEq/L) Before and 24 hours after surgery
Other Diuresis Total volume of urine within 24 hours of surgery Within 24 hours of surgery
Other Hemofiltration use Proportion of patients undergoing hemofiltration During cardiopulmonary bypass
Other Fluid balance Net fluid balance (intake minus output) calculated using a cumulative fluid chart Daily in ICU from admission to hospital discharge or 5 days maximum (whichever occurs first)
Other Acute kidney injury Acute kidney injury as measured by peak postoperative creatinine and KDIGO Start of surgery to hospital discharge or 5 days maximum (whichever occurs first)
Other Length of hospital stay Length of hospital stay (days) Time from admission to hospital discharge or 5 days maximum (whichever occurs first)
Other Major adverse cardiovascular events Composite outcome of cardiovascular death, non-fatal myocardial infarction or stroke Start of surgery to hospital discharge or 5 days maximum (whichever occurs first)
Primary Feasibility Outcomes Feasibility will be established in the pilot phase if all the following criteria are met:
Average recruitment rate of 7 patients per week.
Complete Hb data before and after cardiopulmonary bypass in 90% of patients.
Compliance of the research team members, OR staff and ward medical staff with the protocol of 90%.
Start to end of study recruitment, which is anticipated to take 20 weeks
Primary Change in hemoglobin concentration during cardiopulmonary bypass Change in arterial hemoglobin concentration during cardiopulmonary bypass Start to end of cardiopulmonary bypass
Secondary Change in hemoglobin concentration after cardiopulmonary bypass Change in arterial hemoglobin concentration from baseline to discharge Start of cardiopulmonary bypass to hospital discharge or 5 days maximum (whichever occurs first)
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A